Abiopharma

🔍 Paolini John F. (Executive)

Company: Kiniksa Pharmaceuticals International, plc (KNSA)

Report Date: 2026-05-01

Detailed Transactions and Holdings:

• Acquired 58,424 shares of Class A Ordinary Share at $10.36 per share (Direct)
  Date: 2026-05-01 | Code: M | equity_swap_involved: 0 | shares_owned_after: 124,047.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 37,327 shares of Class A Ordinary Share at $53.52 per share (Direct)
  Date: 2026-05-01 | Code: S | equity_swap_involved: 0 | shares_owned_after: 86,720.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Sold 21,097 shares of Class A Ordinary Share at $54.04 per share (Direct)
  Date: 2026-05-01 | Code: S | equity_swap_involved: 0 | shares_owned_after: 65,623.00 | transaction_form_type: 4 | Footnotes: F1, F3
• Sold 58,424 shares of Share Option at $10.36 per share (Derivative)
  Date: 2026-05-01 | Code: M | Expires: 2028-02-29 | equity_swap_involved: 0 | shares_owned_after: 29,670.00 | transaction_form_type: 4 | Footnotes: F1, F4

Footnotes:

• F1: This transaction was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on November 18, 2025.
• F2: This transaction was executed in multiple trades through a broker-dealer at prices ranging between $52.765 and $53.76. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
• F3: This transaction was executed in multiple trades through a broker-dealer at prices ranging between $53.765 and $54.22. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
• F4: The option is fully vested and exercisable.